A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)

NCT05096221 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

126

Enrollment

INDUSTRY

Sponsor class

Conditions

Duchenne Muscular Dystrophy

Interventions

GENETIC: delandistrogene moxeparvovec
GENETIC: placebo

Sponsor

Sarepta Therapeutics, Inc.

Collaborators

[object Object]